Previous Close | 2.3900 |
Open | 2.3500 |
Bid | 2.4200 x 800 |
Ask | 2.8400 x 900 |
Day's Range | 2.3500 - 2.4400 |
52 Week Range | 1.5000 - 3.9000 |
Volume | |
Avg. Volume | 134,818 |
Market Cap | 287.697M |
Beta (5Y Monthly) | 1.81 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.2600 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 7.58 |
Subscribe to Yahoo Finance Plus to view Fair Value for IMMP
Data from the safety lead-in of the AIPAC-003 trial shows 90mg efti in combination with paclitaxel is safe and well toleratedEncouraging initial efficacy in six metastatic breast cancer patients, who exhausted all endocrine therapy including CDK4/6 inhibitors, demonstrated by a 50% overall response rate, including one complete response, and a 100% disease control rate SYDNEY, AUSTRALIA, March 05, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a cl
Key Insights Immutep's significant individual investors ownership suggests that the key decisions are influenced by...
In this piece, we will take a look at the ten best Australian stocks to buy. If you want to skip our coverage of some of the biggest stocks in Australia and how you might trade them, then you can skip ahead to 5 Best Australian Stocks To Buy. When we talk about the fundamentals […]